超大剂量东菱克栓酶对超早期脑梗塞溶栓治疗的影响

Affection of a overmuch dosage of the batroxobin to the thrombolytic treatment of patients with acute cerebral infarction in the early period

应用东菱克栓酶对34例急性脑梗塞患者采用1:1配对法观察溶栓治疗,按常规方法小剂量组用药20单位,大剂量组用药40单位。结果1-30天内后者比前者疗效提高39.6%,特别在1-7天内提高61.4%,则8-30天内两组疗效相同。两组发病治疗时间6和12h 内的疗效无明显差别。治疗10天大剂量组 MR 中 T_2相高信号区范围有明显缩小,整个观察中无出血性并发症。上述表明东菱克栓酶安全性较大,增量使用可提高疗效,溶栓时间窗不宜限于6h 之内。

Batroxobin(DF-521)was used for thrombolytic therapy in 34 patients with acute cerebral infarction,who were observed by 1:1 matched method.The dosage of small dose group was 20 units in the routine treatment and 40 units in the large deose one.The result showed the curative effect of the large dose group was increased by 39.6% more than the small dose one during 1-30 days, especially by 61.4% during 1-7days,and the improved dgrees of the two groups were similar during 8～30 doys.The therapeutic effect of the tow periods wasnt,of significant difference when batroxobin was used in 6 or 12 hours after onset.The area of T_2 hight signal became reduced obviously in MR of the large one on the 10th day.No complication of bleeding occured in all observed course.The paper demonstrated that it is safer to use batroxobin,its increased dose might raise the therapeutic effect,and the window of thrombolytic time mustn't be linited within 6 hours.